Accordingly, Bojarczuk et al. compared molecules targeting different isoforms of class I PI3K in human DLBCL cell lines and showed that most of the analyzed cell lines were more sensitive to a pan-PI3K inhibitor (pictilisib) than to selective PI3K-α, -β, -δ and dual -β/δ inhibitors [10]. This evidence concerns the gene PIK3CG and diffuse large B-cell lymphoma.